


## Curriculum Vitae

<b>Name</b>	<b>Yeon Hee Park</b>	
<b>Current Position &amp; Affiliation</b>	<b>Professor Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</b>	
<b>Country</b>	<b>Korea, Republic of</b>	
<b>Educational Background</b>		

1993 EWHA Womans University College of Medicine (M.D.)  
2001 KYUNGHEE University College of Medicine (Ph.D.)

### Professional Experience

- 2006. 2 – 2007. 12**      Research Scholar, Moore Cancer Center, UCSD, San Diego, USA  
 Research Scholar, Sydney Kimmel Cancer Center, San Diego, USA
- 2008. 3 – 2014. 2**      ASSOCIATE PROFESSOR, DEPARTMENT OF HEMATOLOGY AND ONCOLOGY, SAMSUNG MEDICAL CENTER, SUNGKYUNKWAN UNIVERSITY, SCHOOL OF MEDICINE, SEOUL, KOREA
- 2014.3 – Present**      PROFESSOR, DEPARTMENT OF HEMATOLOGY AND ONCOLOGY, SAMSUNG MEDICAL CENTER, SUNGKYUNKWAN UNIVERSITY, SCHOOL OF MEDICINE, SEOUL, KOREA
- 2017-2021. 3**          Director, Breast Cancer Center, SMC
- 2021-Present**          Director, Clinical Trial Center, SMC
- 2018-Present**          Director of International Cooperation Committee, Korean Society of Medical Oncology (KSMO)
- 2019-Present**          Director of Breast Cancer Committee, Korean Cancer Study Group (KCSG)

---

**Professional Organizations**

---

**KSMO, KCSG, KCA,  
ASCO  
ESMO  
BIG  
TRIO**

---

**Main Scientific Publications**

---

1. Park YH, Kim YH, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol* 2019; 20: 1750-59.
2. Kan Z, Ding Y, Kim J, et al. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. *Nature Communications* 2018; 9: 1725
3. Park SE, Park K, Lee E, et al. Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer. *Oncoimmunology*, 2018; 7: e1466768
4. Kim JY, Park K, Im SA, et al. Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. *Breast Cancer Res Treat* 2020; 184: 743-753.
5. Park YH, Senkus-Konefka E, IM SA, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO, and TOS. *Annals of Oncology* 2020; 31: 451-469
6. Park YH, Lee KH, Sohn JH, et al. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. *International Journal of Cancer* 2018; 143: 3240-47.
7. Kim JY, Kang D, Nam SJ, et al. Clinical features and outcomes of invasive breast cancer: Age-specific analysis of a modern hospital-based registry. *Journal of Global Oncology* 2019; 1-9.
8. Park S, Lee E, Park S, et al. Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer. *Molecular Cancer Research* 2020; 18: 1315-25.
9. Lu YS, Lee K, Chao TY, et al. A phase Ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER-negative advanced breast cancer. *Clinical Cancer Research* 2020 doi:10.1158/1078-0432

10. Lee S, Im SA, Kim GM, et al. Patient-reported outcomes of pabociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer: A prospective, open-label, randomized phase II trial (KCSG-BR 15-10) *Cancers* 2020 Nov 5; 12(11):E3265.
  11. Hur JY, Kim JY, Ahn JS, et al. Clinical characteristics of Korean breast cancer patients who carry pathogenic germline mutations in both BRCA1 and BRCA2: A single-center experience. 2020 May 21;12(5):1306.
  12. Schmid P, Cortes J, Puztai L. et al. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med* 2020; 382: 810-821.
  13. Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med* 2020; 382: 610-621.
  14. Yap YS, Lu YS, Tamura K, et al. Insights into breast cancer in the east vs west: A review. *JAMA Oncol* 2019
  15. Park YH, Lal S, Lee JE, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. *Nature Communications* 2020
-